Marijn E. Dekkers - 07 Jun 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2023, 16:15:12 UTC
Prior SEC filing: 14 Feb 2023
Next SEC filing: 20 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark Bodenrader, as Attorney-in-Fact

Key filing fact

Marijn E. Dekkers filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 09 Jun 2023.

Key facts

This page summarizes Marijn E. Dekkers's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2023, 16:15.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CERE transaction

Common Stock

Award

Transaction value
Shares: +3,282
Change %: +11%
Price
Shares after: 31,822
Date: 07 Jun 2023
Ownership: Direct
Footnotes: F1

CERE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 602,326
Date: 07 Jun 2023
Ownership: See footnote
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CERE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +13,780
Change %
Price: $0.000000
Shares after: 13,780
Date: 07 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,780
Exercise price: $32.60
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.

Footnote F2

On June 7, 2023, BC Perception Holdings, LP ("BC Perception") distributed an aggregate of 432,627 shares of Common Stock to certain of its limited partners (including Novalis LifeSciences Investments I, L.P., "Novalis LifeSciences") in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. Includes 402,326 shares of Common Stock received by Novalis LifeSciences in the distribution described herein made in accordance with the exemptions afforded under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended.

Footnote F3

Represents shares held by Novalis LifeSciences. The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F4

100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.